[1]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140-143.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
　Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):140-143.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
点击复制

硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
39
期数:
2015年第2期
页码:
140-143
栏目:
出版日期:
2015-03-25

文章信息/Info

Title:
Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I
作者:
胡小春;  蒋宁一;  李敬彦;  张弘;  刘生;  卢献平;  梁九根;  张占磊
中山大学孙逸仙纪念医院核医学科, 广州, 510120
Author(s):
Hu Xiaochun;  Jiang Ningyi;  Li Jingyan;  Zhang Hong;  Liu Sheng;  Lu Xianping;  Liang Jiugen;  Zhang Zhanlei
Department of Nuclear Medicine, Sun Yet-san Memorial Hospital, Sun Yet-san University, Guangzhou 510120, China
关键词:
硒; 碘放射性同位素; 格雷夫斯病; 甲状腺过氧化物酶抗体
Keywords:
Selenium; Iodine radioisotopes; Graves disease; Thyroid peroxidase antibody
DOI:
10.3760/cma.j.issn.1673-4114.2015.02.008
摘要:
目的 探讨Graves病患者经131I治疗后,补硒对患者血清甲状腺过氧化物酶抗体(TPOAb)水平的影响。方法 选取TPOAb水平为10~1300 IU/ml的Graves病患者266例,其中,TPOAB范围在10~60 IU/ml为阴性,TPOAb>60 IU/ml为阳性。将所有患者随机分成对照组(112例)和硒治疗组(154例),对照组经131I治疗后行常规治疗,硒治疗组经131I治疗后行常规治疗及服硒制剂(100μg/次,2次/d),比较两组治疗后6、12个月TPOAb水平及TPOAb阳性率的变化。结果 治疗后6个月,两组TPOAb水平较治疗前均明显上升,且差异有统计学意义(对照组:Z=-2.084,P<0.05;硒治疗组:Z=-2.112,P<0.05),但两组之间的差异无统计学意义(Z=-0.764,P>0.05);治疗后12个月,对照组TPOAb水平与治疗前相比差异无统计学意义(Z=-1.538,P>0.05),硒治疗组TPOAb水平与治疗前相比差异有统计学意义(Z=-5.465,P<0.01),两组间比较差异有统计学意义(Z=-2.180,P<0.05);两组TPOAb水平阳性率在治疗后6、12个月与治疗前相比无明显变化(对照组:χ12=0.720、χ22=0.103,P均>0.05;硒治疗组:χ12=0.023、χ22=0.340,P均>0.05),两组间比较差异亦无统计学意义(χ12=0.001、χ12=0.366,P均>0.05).结论 补硒能有效降低经131I治疗的Graves病患者的血清TPOAb水平,对血清高水平TPOAb的降低尤为明显。
Abstract:
Objective To explore the effect of additional selenium on the serum levels of thyroid peroxidase antibody(TPOAb) after treatment of Graves disease with 131I.Methods A total of 266 patients with TPOAb levels between 10 and 1 300 IU/ml participated in this study.TPOAb levels within 10 IU/ml to 60 IU/ml were considered negative, and levels greater than 60 IU/ml were considered positive.All patients were randomly dividedinto control(n=112) and seleniumtreatment group(n=154).Aftertreatment with 131I, the control group received conventional therapy, whereas the selenium treatment group received additional selenium(100kg twice a day).The TPOAb levels and positive ratios of the two groups were compared with pre.therapy levels after treatment for 6 and 12 months.Results After 6 months, the TPOAb levels in both groups significantly increased compared with the pre-therapy levels(control group: Z=-2.084.P<0.05;selenium treatment group:Z=-2.112, P<0.05).However, no significant difference existed in the TPOAb levels between the two groups(Z=-0.764, P>0.05).After 12 months, the TPOAb levels in the control group did not change significantly compared with the pre-therapy levels(Z=-1.538.P>0.05), whereas the TPOAb levels in the selenium treatment group significantly decreased compared with the pre-therapy levels(Z=-5.465, P<0.01).The difference between the two groups were statistically significant(Z=-2.180, P<0.05).The positive ratios of TPOAb for both groups did not change significantly 6 or 12 months after 131I therapy(control group:χ12=0.720, χ22=0.103, both P>0.05;selenium treatment group:χ12=o.023, χ22=0.340, both P>0.05).Overall, the positive ratios were not statistically significant be-tween the two groups(χ12>0.001, χ22=0.366, both P>0.05).Conclusions Additional treatment with sele-nium after 131I therapy for Graves disease can effectively decrease the TPOAb levels, especially for patients with high initial TPOAb levels.

参考文献/References:

[1]朱翠颜,王筱菁,邓承宗.硒对弥漫性毒性甲状腺肿自身免疫抗体的影响[J].吉林医学,2013,34(16):3147-3148.
[2]姜云生.硒酵母治疗桥本病100例分析[J]吉林医学,2014,35(11):2303-2304.
[3] Mariotti S,Caturegli P,Piccolo P,et al.Antithyroid peroxidase an-toantibodies in thyroid diseases[J].J Clin Endocrinol Metab,1990,71(3):661-669.
[4] Rayman MP.Selenium and human health[J].Lancet,2012,379(9822):1256-1268.
[5] Fairweather-Tait SJ,Bao YP,Broadley MR,et al.Selenium in hu-man health and disease[J].Antioxid Redox Signal,2011,14(7):1337-1383.
[6] Duntas LH.Selenium and the thyroid:a close-knit connection[J].J Clin Endocrinol Metab,2010,95(12):5180-5188.
[7] 刘莉,平智广,朱本章.自身免疫性甲状腺病患者血清硒水平[J].中华内分泌代谢杂志,2005,21(6):537-538.
[8] 屈伟,王社教,封娟毅,等.Graves甲亢患者131碘治疗后血清TPOAb、TGAb抗体变化的临床意义[J].陕西医学杂志,2010,39(2):205-207.
[9] Turker O,Kumanlioglu K,Karapolat I,et al.Selenium treatment in autoimmune thyroiditis:9-month follow-up with variable doses[J].J Endocrinol,2006,190(1):15l-156.
[10] Duntas LH,Mantzou E,Koutras DA.Effects of a six month treat-ment with selenomethionine in patients with autoimmune thyroiditis[J]. Eur J Endocrinol,2003,148(4):389-393.
[11] Gartner R,Gasnier BC,Dietrich JW,et al.Selenium supplementa tion in patients with autoimmune thyroiditis decreases thyroid per oxidase antibodies concentrations[J].J Clin Endocrinol Metab,2002,87(4):1687-1691.
[12] Anastasilakis AD,Toulis KA,Nisianakis P,et al.Selenomethionine treatment in patients with autoimmune thyroidifis:a prospective quasi-randomised trial[J].Int J Clin Pratt,2012,66(4):378-383.
[13] 朱琳,白雪,滕卫平,等.硒对自身免疫性甲状腺炎自身抗体的影响[J].中华医学杂志,2012,92(32):2256-2260.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
　Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[3]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[4]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
　yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[5]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
　Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[6]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
　Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[7]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[8]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[9]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
　Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[10]杨翠红,刘金剑,褚丽萍,等.125I标记注射用干扰素α2b(假单胞菌)研究雾化吸入与肌肉注射的代谢及组织分布差异[J].国际放射医学核医学杂志,2015,39(3):191.[doi:10.3760/cma.j.issn.1673-4114.2015.03.001]
　Yang Cuihong,Liu Jinjian,Chu Liping,et al.Pharmacokinetics and tissue distribution of interferon α2b（Pseudomonas putida）administered via atomization inhalation and intramuscular injection by 125I labeling[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):191.[doi:10.3760/cma.j.issn.1673-4114.2015.03.001]

备注/Memo

备注/Memo:
收稿日期:2014-10-22。
通讯作者:蒋宁一,Email:ningyij@163.net
更新日期/Last Update: 1900-01-01